Centre Hospitalier De Perpignan
- Address
- lock Available on a paid plan
Centre Hospitalier De Perpignan - Comprehensive Cancer and Blood Disorders Research
Centre Hospitalier De Perpignan is a leading medical research institution with extensive expertise in hematological malignancies and oncology. The center participates in cutting-edge clinical trials spanning multiple therapeutic areas, with particular strength in blood cancers and solid tumors. Their research portfolio demonstrates a commitment to advancing treatment strategies across both common and rare conditions.
- Hematological malignancies including acute lymphoblastic leukemia, chronic lymphocytic leukemia, multiple myeloma, myelodysplastic syndromes, and various lymphomas
- Gastrointestinal cancers, particularly pancreatic, colorectal, and esophageal adenocarcinomas with focus on innovative chemotherapy combinations
- Autoimmune and inflammatory conditions including giant cell arteritis, ANCA-associated vasculitis, and eosinophilic granulomatosis with polyangiitis
- Infectious diseases management including prosthetic joint infections, candidemia, and bartonellosis
The center's research approach emphasizes precision medicine and minimal residual disease monitoring, particularly in hematological conditions. Their participation in major cooperative group trials demonstrates expertise in complex treatment protocols involving novel immunotherapies, bispecific antibodies, and targeted agents. The institution also contributes to pediatric research, cardiovascular protection studies, and neurological interventions, positioning it as a comprehensive clinical research hub serving diverse patient populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 17 therapeutic areas and 15 of 128 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 105 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 21 by active trials.
lock +20 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +11 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Hospitalier De Perpignan
lock Showing 1 of 69 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Comparative Efficacy and Safety of Tocilizumab Versus Adalimumab in Severe Uveitis Associated with Behçet’s Disease: A Multicenter Randomized Trial | Assistance Publique Hopitaux De Paris | Phase II | Recruiting | Apr 2024 | — |
IMP list
lock Showing 1 of 128 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Oxaliplatin | 11 | Unknown | 2017-06-28 | 2024-11-08 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.